StockData

Jazz Pharmaceuticals vs United Therapeutics

JAZZ and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How JAZZ and UTHR compare

United Therapeutics is the larger company, worth 1.6 times as much as Jazz Pharmaceuticals ($25.2B against $15.6B).

On earnings, United Therapeutics is cheaper: it trades at 21.0× trailing earnings, against 78.1× for Jazz Pharmaceuticals.

Jazz Pharmaceuticals grew revenue faster over the last twelve months (13.5% versus 2.5% for United Therapeutics).

United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 4.4% at Jazz Pharmaceuticals.

United Therapeutics scores higher on the StockData Score (11 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricJAZZUTHR
Size and price
Market cap$15.6B$25.2B
Share price$239.77$587.88
Change, 1 year69.2%27.2%
Change, 5 years93.2%204%
Beta (5Y)0.200.44
Employees2,8901,400
StockData Score
Total score711 (better)
Valuation score01 (better)
Growth score22
Performance score35 (better)
Health score23 (better)
Dividend score00
Valuation
P/E78.1×21.0× (better)
P/S3.3× (better)8.0×
P/B3.7× (better)3.9×
EV/EBITDA42.9×15.1× (better)
P/FCF9.6× (better)23.1×
PEG–0.92
FCF yield10.4% (better)4.3%
Fair value$108.36$480.40
Margin of safety−121%−22.4% (better)
Growth
Revenue growth (TTM)13.5% (better)2.5%
Revenue growth, 5Y average12.5%16.5% (better)
Net income growth (TTM)–5.5%
EPS growth (TTM)–9.0%
EPS growth, 5Y average–19.3%
Profitability
Gross margin–86.1%
Operating margin9.0%44.4% (better)
Net margin4.4%41.6% (better)
FCF margin34.4%34.6% (better)
Return on equity5.1%19.3% (better)
Return on invested capital4.5%29.7% (better)
Financial health
Debt / equity1.33–
Net debt / EBITDA6.37–
Interest coverage–117×
Current ratio1.825.73 (better)
Altman Z-score1.9621.79 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Buyback yield–9.9%
Shareholder yield0.00%9.9% (better)
Ownership
Held by institutions99.2%97.4%
Held by insiders3.4%9.1%
Insider net buying, 12 months−$67.1M (better)−$1.4B
Superinvestors holding1–
Short interest, % of float9.3%4.7%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.